US20150164823A1 - Cholecystokinin secretion-promoting composition - Google Patents
Cholecystokinin secretion-promoting composition Download PDFInfo
- Publication number
- US20150164823A1 US20150164823A1 US14/630,911 US201514630911A US2015164823A1 US 20150164823 A1 US20150164823 A1 US 20150164823A1 US 201514630911 A US201514630911 A US 201514630911A US 2015164823 A1 US2015164823 A1 US 2015164823A1
- Authority
- US
- United States
- Prior art keywords
- trans
- secretion
- cck
- double bond
- aldehyde
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
- C07C47/21—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a cholecystokinin secretion-promoting composition, more specifically, a cholecystokinin secretion-promoting composition useful as an appetite suppressant.
- Obesity refers to a state of having a larger body weight or a state of having an excessive accumulation of body fat compared to a normal state.
- Obesity is a contemporary lifestyle disease caused by biased dietary habits, lack of exercise, or lack of sleep.
- Obesity caused by a metabolic disorder or an endocrine disease is called symptomatic obesity.
- Either obesity can be a risk factor of diseases such as hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hypertension, arteriosclerosis, ischemic heart disease, stroke, and arteriosclerosis obliterans. Accordingly, prophylaxis or treatment of obesity can be an effective means for preventing these diseases.
- CCK Cholecystokinin
- Patent Literature 1 Artinine-containing peptide having a cholecystokinin secretion-stimulating activity and food containing the peptide discloses that a pepsin digestion product of soybean ⁇ -conglycinin promotes the CCK-secreting activity in rats to reduce the food intake and that the soybean ⁇ -conglycinin is used in a food intake-suppressing food.
- Non-Patent Literatures 2 and 3 (“Soybean ⁇ -Conglycinin Bromelain Hydrolysate Stimulates Cholecystokinin Secretion by Enteroendocrine STC-1 Cells to Suppress the Appetite of Rats under Meal-Feeding Conditions” and “Acute effect of soybean beta-conglycinin hydrolysate ingestion on appetite sensations in healthy humans”) report on that a bromelain hydrolysate of soybean ⁇ -conglycinin having a CCK secretion-promoting action suppresses the appetite of rats and human beings.
- Non-Patent Literature 4 (Development of peptide regulating appetite by controlling a gastrointestinal hormone with high safety) reports on a food containing a bromelain digestion product or peptide of ⁇ -conglycinin.
- Patent Literature 2 (Composition containing pork-derived peptide having a food intake-suppressing action) discloses a composition containing a peptide having a cholecystokinin secretion-stimulating activity or food intake-suppressing activity prepared by digesting pork or pork-derived protein with pepsin on the basis that the pig-derived peptide promotes CCK secretion and reduces the food intake of rats.
- Patent Literature 3 discloses a pharmacological composition for suppressing appetite containing an ingredient showing a cholecystokinin secretion-stimulating action prepared from yeast. This ingredient is low in calorie and has high heat resistance and high enzymolysis resistance.
- CCK secretion-promoting materials such as a degradation product of ⁇ -conglycinin and a pig-derived peptide, and that these materials cause advantageous effects, such as a delay in the excretion of gastric contents, a reduction in food intake, and an increase in the feeling of fullness, in animals including human beings.
- the present invention provides a cholecystokinin secretion-promoting composition (hereinafter, referred to as CCK secretion-promoting agent) as an active component, acrylic acid and/or an unsaturated aldehyde having a main chain of 4 to 12 carbon atoms having a double bond in at least position 2 or 4, wherein the main chain has 4 to 9 carbon atoms if there is a double bond in only position 2, and the main chain has 9 to 12 carbon atoms if there is a double bond in only position 4.
- CCK secretion-promoting agent cholecystokinin secretion-promoting composition
- cholecystokinin produced by I cells in the small intestine is physiologically promoted by peptides, amino acids, and fatty acids in the duodenum.
- peptides such as degradation products of ( ⁇ -conglycinin), proteins (whey and casein), fatty acids, and calcium are conventionally known to promote the secretion of CCK.
- ⁇ -conglycinin degradation products of ( ⁇ -conglycinin), proteins (whey and casein), fatty acids, and calcium
- the unsaturated aldehydes and other materials specified by the present invention have a CCK secretion-stimulating activity.
- the unsaturated aldehyde is preferably selected from the group consisting of di-unsaturated aldehydes having 4 to 12 main-chain carbon atoms and having double bonds in positions 2 and 4, mono-unsaturated aldehydes having 4 to 9 main-chain carbon atoms and having a double bond in position 2, and mono-unsaturated aldehydes having 9 to 12 main-chain carbon atoms and having a double bond in position 4.
- the CCK secretion-promoting agent preferably comprises the unsaturated aldehyde having a double bond in position 2.
- the CCK secretion-promoting agent preferably comprises the unsaturated aldehyde having double bonds in positions 2 and 4.
- the unsaturated aldehydes are preferably in trans conformations.
- the CCK secretion-promoting agent preferably comprises the unsaturated aldehyde having two double bonds and the unsaturated aldehyde having one double bond, or comprises the unsaturated aldehyde having two different double bonds.
- the unsaturated aldehyde having one double bond is preferably trans-2-octenal.
- the present invention also provides an appetite suppressant including the CCK secretion-promoting agent.
- the present invention also provides an appetite-suppressing food product including the CCK secretion-promoting agent.
- the present invention relates to a novel CCK secretion-promoting agent containing a specific unsaturated aldehyde as an active ingredient.
- Some examples of the unsaturated aldehyde used in the present invention have been confirmed to be safe as food additives. These unsaturated aldehydes are inexpensively available and can be easily processed into a solution or a solid. Thus, the unsaturated aldehydes are superior to conventional CCK secretion-promoting materials in these points.
- the CCK secretion-promoting agent of the present invention promotes the activity of secreting cholecystokinin, resulting in a reduction in food intake and also a decrease in the sensation of hunger.
- the CCK secretion-promoting agent of the present invention can be used as, for example, an appetite suppressant, hyperphagia preventive agent, or obesity preventive agent.
- the present invention can also provide an appetite-suppressing food product that induces a feeling of fullness with a small amount thereof.
- the appetite-suppressing food product can be prepared by adding a cholecystokinin secretion-promoting composition of the present invention to a foodstuff.
- the CCK secretion-promoting agent of the present invention comprises acrylic acid and/or an unsaturated aldehyde having 4 to 12 main-chain carbon atoms and a double bond in at least position 2 or 4. It has been revealed that acrylic acid and/or a specific unsaturated aldehyde used in the present invention has a high CCK-secreting activity, whereas saturated aldehydes, saturated or unsaturated alcohols, saturated fatty acids, unsaturated fatty acid excluding acrylic acid, and saturated or unsaturated hydrocarbons have a low CCK secretion-stimulating activity.
- the mono-unsaturated aldehyde having a double bond in only position 2 has 4 to 9 main-chain carbon atoms. If the number of carbon atoms in the main chain is at least 10, the CCK-secreting activity decreases.
- the mono-unsaturated aldehyde having a double bond in only position 4 has 9 to 12 main-chain carbon atoms. If the number of carbon atoms in the main chain is not more than 8, the CCK-secreting activity decreases.
- an unsaturated aldehyde having three main-chain carbon atoms and having a double bond in position 2 propenal, also has a CCK-secreting activity
- GSS Globally Harmonized System of Classification and Labeling of Chemicals
- propenal is believed to be highly toxic and is inadequate as a CCK secretion-promoting agent that is ingested to human beings.
- Some unsaturated aldehydes having more than 12 main-chain carbon atoms are solid at ordinary temperature and are predicted to cause separation or precipitation when they are used in liquid formulations or foods. Thus, such unsaturated aldehydes may be restricted in the use.
- unsaturated aldehydes having a double bond in a position other than positions 2 and 4 the CCK-secreting activity is low.
- Examples of the CCK secretion-promoting agent include trans,trans-2,4-hexadienal, trans,trans-2,4-heptadienal, trans,trans-2,4-nonadienal, trans,trans-2,4-decadienal, trans,trans-2,4-dodecadienal, 2,3-butadienal, 2,4-pentadienal, 3,4-pentadienal, 2,7-octadienal, 2,6-octadienal, 2,4-octadienal, 2,6-nonadienal, 4,7-decadienal, 2,4-undecadienal, 2,6-dodecadienal, 3,7-dimethyl-2,6-nonadienal, trans-2-methyl-2,6-heptadienal, 2,4-dimethyl-2,6-heptadienal, 3,6-dimethyl-2,5-heptadienal, 3,7-d
- the unsaturated aldehyde is preferably selected from the group consisting of di-unsaturated aldehydes having 4 to 12 main-chain carbon atoms and having double bonds in positions 2 and 4, mono-unsaturated aldehydes having 4 to 9 main-chain carbon atoms and having a double bond in position 2, and mono-unsaturated aldehydes having 9 to 12 main-chain carbon atoms and having a double bond in position 4.
- Examples of such an unsaturated aldehyde include trans,trans-2,4-hexadienal, trans,trans-2,4-heptadienal, trans,trans-2,4-nonadienal, trans,trans-2,4-decadienal, trans,trans-2,4-dodecadienal, 2-butenal, trans-2-heptenal, trans-2-octenal, trans-2-nonenal, trans-4-decenal, and cis-4-decenal.
- the CCK secretion-promoting agent of the present invention preferably contains an unsaturated aldehyde having a double bond in position 2.
- unsaturated aldehyde include trans,trans-2,4-hexadienal, trans,trans-2,4-heptadienal, trans,trans-2,4-nonadienal, trans,trans-2,4-decadienal, trans,trans-2,4-dodecadienal, 2-butenal (crotonaldehyde), trans-2-heptenal, trans-2-octenal, and trans-2-nonenal.
- the CCK secretion-promoting agent containing an unsaturated aldehyde having double bonds in positions 2 and 4 has a higher CCK-secreting activity and is particularly preferred.
- unsaturated aldehyde include trans,trans-2,4-hexadienal, trans,trans-2,4-heptadienal, trans,trans-2,4-nonadienal, trans-trans-2,4-decadienal, and trans,trans-2,4-dodecadienal.
- the unsaturated aldehyde is preferably in a trans conformation.
- the CCK secretion-promoting agent preferably contains an unsaturated aldehyde having two double bonds and an unsaturated aldehyde having one double bond or contains two different unsaturated aldehydes having two double bonds. It has been revealed that the combination of two or more different unsaturated aldehydes synergistically promotes the activity of secreting cholecystokinin.
- the unsaturated aldehyde having only one double bond preferably has eight or less carbon atoms and is more preferably trans-2-octenal.
- the unsaturated aldehyde having two double bonds is preferably trans,trans-2,4-hexadienal, trans,trans-2,4-heptadienal, or trans,trans-2,4-decadienal.
- one of the unsaturated aldehydes is preferably trans,trans-2,4-heptadienal.
- the CCK secretion-promoting agent of the present invention induces, for example, a delay in the excretion of gastric contents, a reduction in food intake (appetite), a decrease in the sensation of hunger, or an increase in the feeling of fullness in animals including human beings, as in the conventional cholecystokinin-secreting activity.
- examples of the use of the CCK secretion-promoting agent of the present invention include appetite suppressants, hyperphagia preventive or therapeutic agents, and obesity preventive or therapeutic agents (hereinafter, referred to as appetite suppressant, etc.).
- the CCK secretion-promoting agent, the appetite suppressant, etc. of the present invention can be provided as drugs or functional foods.
- the content of the unsaturated aldehyde in the CCK secretion-promoting agent or the appetite suppressant, etc. is usually 0.005% to 60% by weight, preferably 0.05% to 30% by weight.
- the CCK secretion-promoting agent and other agents of the present invention can contain pharmacologically or bromatologically acceptable other additives within a range that does not impair the effects of the present invention, in addition to the unsaturated aldehyde as an active ingredient.
- additives include excipients such as corn starch, crystalline cellulose, and lactose; disintegrators such as starch, sodium alginate, gelatin, calcium carbonate, and calcium citrate; binding agents such as methyl cellulose and its salts, ethyl cellulose, gum arabic, and gelatin; lubricants such as talc, magnesium stearate, polyethylene glycol, and hydrogenated vegetable oils; xanthine derivatives; pH adjusters; cooling agents; suspending agents; viscous agents; solubilizers; antioxidants; coating agents; plasticizers; surfactants; water; alcohols; water-soluble polymers; sweeteners such as fructose, glucose, and sorbitol; corrigents; acidifiers such as citric acid; flavoring agents; coloring agents; vitamins; minerals; and lipids.
- excipients such as corn starch, crystalline cellulose, and lactose
- disintegrators such as starch, sodium alginate, gelatin, calcium carbonate, and
- the CCK secretion-promoting agent and other agents of the present invention may be in any form.
- examples of the form include solid formulations such as powders, granules, capsules, pills, tablets, chewable tablets, and drops; and liquid formulations such as drinkable preparations, liquid agents, suspensions, emulsions, syrups, and dry syrups.
- the CCK secretion-promoting agent and other agents of the present invention may be administered in any route.
- the drug may be administered orally or parenterally (e.g., intravenous injection, intramuscular injection, subcutaneous injection, intraperitoneal administration, rectal administration, or transdermal administration).
- the CCK secretion-promoting agent and other agents of the present invention are desirably ingested before foods reach the duodenum. As shown by the cell test described below, since the CCK secretion-promoting agent produces the effect within 60 minutes after the ingestion, specifically, the CCK secretion-promoting agent and other agents of the present invention is preferably ingested before or during the meal.
- the dosage varies depending on the age, body weight, and anamnesis (e.g., obesity) of a patient to whom the agent is administered.
- the daily dosage of the unsaturated aldehyde is usually 0.5 to 10 mg/kg of body weight, preferably 1 to 5 mg/kg of body weight, for an adult.
- the ingestion amount varies depending on the age, body weight, and anamnesis (e.g., obesity) of a subject who ingests the agent.
- the daily ingestion of the unsaturated aldehyde is usually 0.5 to 10 mg/kg of body weight, preferably 1 to 5 mg/kg of body weight, for an adult.
- the present invention also provides an appetite-suppressing food product containing the CCK secretion-promoting agent.
- the food include feeds for pets.
- a food containing the CCK secretion-promoting agent of the present invention can suppress food ingestion.
- the food include, but not limited to, common processed foods and drinks, for example, side dishes such as salads, fried foods, tofu, and konnyaku; soups; bread, rice, and noodles; confectionery such as cookies, muffins, cakes, chips, snack confectionery, chocolates, jellies, puddings, chewing gum, and candies; dairy products such as yogurt and milk; fish meat pastes such as ham, sausages, and boiled fish pastes; drinks such as coffee, juices, and sports beverages; and flavorings such as dressings, soy sauce, and sauces.
- the amount of the unsaturated aldehyde in an appetite-suppressing food product containing the CCK secretion-promoting agent is preferably 0.001% to 0.03% by weight, preferably 0.003% to 0.015% by weight.
- aldehydes having 3 to 13 main-chain carbon atoms and having 0 to 2 double bonds in the main chain ketones, alcohols, fatty acids, and hydrocarbons were prepared.
- 70 mM KCl (positive control) causing hormone release by depolarization was prepared.
- test materials were divided into five groups as shown in Table 1. In order to solve the discontinuity between experimental groups, every group included trans,trans-2,4-decadienal. Each test material was tested three times, and the average value of the results was calculated.
- test materials were each dissolved in ethanol, and each solution was diluted with Hepes buffer (140 mM NaCl, 4.5 mM KCl, 20 mM Hepes, 1.2 mM CaCl 2 , 1.2 mM MgCl 2 , and 10 mM D-glucose, pH 7.4) to give a 0.1 vol % ethanol solution, which was used as the evaluation solution.
- Hepes buffer 140 mM NaCl, 4.5 mM KCl, 20 mM Hepes, 1.2 mM CaCl 2 , 1.2 mM MgCl 2 , and 10 mM D-glucose, pH 7.4
- Mouse intestinal CCK-producing cell line STC-1 was cultured in a 48-well plate for two to three days until subconfluent in a Dulbecco's modified Eagle's medium containing 10% bovine fetal serum at 37° C. in the presence of 5% CO 2 . After the wells were washed with Hepes buffer, 100 ⁇ L of the evaluation solution containing 100 ⁇ M of a test material was added to a well, followed by incubation at 37° C. for 60 minutes. The supernatant was collected and was centrifuged (800 ⁇ g, 5 mM, 4° C.) to precipitate the exfoliated cells. The resulting supernatant (80 ⁇ L) was collected and was cryopreserved. The concentration of CCK in the supernatant was measured with a commercially available enzyme immunoassay kit (manufactured by Phoenix Pharmaceuticals, Inc.).
- the secretion amount of CCK varied from 10 to 30 pM among the tests of a vehicle (i.e., a blank).
- the secretion amounts of CCK in the tests for test materials (100 ⁇ M) of Examples 1 to 12 reached 30 to 60 pM and were always two to three times that by the vehicle, whereas the secretion amounts of CCK in the tests for test materials of Comparative Examples were equivalent to that by the vehicle or lower than that by the vehicle in some cases.
- acrylic acid and the specific unsaturated aldehydes used in Examples have a CCK secretion-stimulating activity.
- Tables 2A and 2B revealed the following: A CCK secretion-stimulating activity was observed in unsaturated aldehydes of Examples 1 to 11 with significant differences.
- the comparison between Examples 1 to 11 and Comparative Examples 15 to 30 demonstrates that alcohols, fatty acids excluding acrylic acid, and hydrocarbons do not have a CCK secretion-stimulating activity, whereas aldehydes have a CCK secretion-stimulating activity.
- the comparison between Examples 1 to 11 and Comparative Examples 1 to 7 demonstrates that the aldehydes must be unsaturated aldehydes.
- the comparison between Examples 1 to 11 and Comparative Examples 12 to 14 demonstrates that a double bond must be present in at least position 2 or 4.
- Example 10 The comparison between Example 10 and Example 11 demonstrates that preferred unsaturated aldehydes are in trans conformations.
- the superiority of the trans conformation is also suggested in that the best results are obtained in Examples 1 to 5 all in trans conformations.
- an ingredient e.g., a degradation product of ( ⁇ -conglycinin) showing a CCK-secreting activity suppresses appetite. Accordingly, it is obvious that the CCK secretion-promoting agent of the present invention also functions as an appetite suppressant.
- Table 3 demonstrates that the CCK-secreting activity is promoted by a combination of an unsaturated aldehyde having two double bonds and an unsaturated aldehyde having one double bond or by a combination of two different unsaturated aldehydes having two double bonds. It has been demonstrated that the CCK-secreting activity is highly promoted, in particular, by a combination of an unsaturated aldehyde having two double bonds and an unsaturated aldehyde having eight or less carbon atoms and one double bond. It has been demonstrated that the CCK-secreting activity is further highly promoted by a combination of an unsaturated aldehyde having double bonds in positions 2 and 4 and trans-2-octenal having a double bond in position 2.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/984,752 US9554990B2 (en) | 2012-09-14 | 2015-12-30 | Cholecystokinin secretion-promoting composition |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012202450 | 2012-09-14 | ||
JP2012202450A JP5951426B2 (ja) | 2012-09-14 | 2012-09-14 | コレシストキニン分泌促進組成物 |
PCT/JP2013/068827 WO2014041885A1 (ja) | 2012-09-14 | 2013-07-10 | コレシストキニン分泌促進組成物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/068827 Continuation WO2014041885A1 (ja) | 2012-09-14 | 2013-07-10 | コレシストキニン分泌促進組成物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/984,752 Continuation US9554990B2 (en) | 2012-09-14 | 2015-12-30 | Cholecystokinin secretion-promoting composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150164823A1 true US20150164823A1 (en) | 2015-06-18 |
Family
ID=50278016
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/630,911 Abandoned US20150164823A1 (en) | 2012-09-14 | 2015-02-25 | Cholecystokinin secretion-promoting composition |
US14/984,752 Expired - Fee Related US9554990B2 (en) | 2012-09-14 | 2015-12-30 | Cholecystokinin secretion-promoting composition |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/984,752 Expired - Fee Related US9554990B2 (en) | 2012-09-14 | 2015-12-30 | Cholecystokinin secretion-promoting composition |
Country Status (5)
Country | Link |
---|---|
US (2) | US20150164823A1 (enrdf_load_stackoverflow) |
JP (2) | JP5951426B2 (enrdf_load_stackoverflow) |
CN (1) | CN104661659B (enrdf_load_stackoverflow) |
IN (1) | IN2015DN00461A (enrdf_load_stackoverflow) |
WO (1) | WO2014041885A1 (enrdf_load_stackoverflow) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3486353A4 (en) * | 2016-06-28 | 2020-03-04 | Kuraray Co., Ltd. | COMPOSITION FOR REMOVAL OF IRON SULFIDE |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170105947A1 (en) * | 2015-10-20 | 2017-04-20 | Julio Lionel Pimentel | Appetite Suppressant Composition |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE902238A1 (en) * | 1989-06-30 | 1991-01-16 | Abbott Lab | Tetrapeptide type-b cck receptor ligands |
DE4030430C1 (de) * | 1990-09-26 | 1993-12-02 | Buck Chem Tech Werke | IR-undurchlässigen Nebel erzeugende Zusammensetzung |
JP3997114B2 (ja) | 2002-06-10 | 2007-10-24 | 独立行政法人科学技術振興機構 | コレシストキニン分泌促進活性を有するアルギニン含有ペプチドおよびこれを含有する食品 |
JP2004135522A (ja) * | 2002-10-16 | 2004-05-13 | Kiyomitsu Kawasaki | 魚節フレーバー組成物および該フレーバー組成物を含有する食品類 |
ES2442865T3 (es) | 2005-09-16 | 2014-02-14 | Janssen Pharmaceutica N.V. | Procedimiento para la preparación de derivados de venzo[E][1,2,4]triazepina-2-ona |
CN101355880B (zh) * | 2006-01-12 | 2012-01-04 | 荷兰联合利华有限公司 | 制造绿茶产品的方法 |
WO2007079900A1 (en) | 2006-01-12 | 2007-07-19 | Unilever Plc | Method for the manufacture of a green tea product |
JP4929455B2 (ja) | 2006-03-03 | 2012-05-09 | 国立大学法人北海道大学 | 摂食抑制作用を有する豚肉由来ペプチドを含有する組成物 |
JP2009084191A (ja) | 2007-09-28 | 2009-04-23 | Kirin Holdings Co Ltd | 食欲抑制用薬理組成物 |
TWI524853B (zh) | 2009-03-27 | 2016-03-11 | Ajinomoto Kk | Give the flavor of the raw material |
JP6071168B2 (ja) * | 2011-01-27 | 2017-02-01 | 日本デルモンテ株式会社 | ブレンドトマトジュース及びその製造方法 |
-
2012
- 2012-09-14 JP JP2012202450A patent/JP5951426B2/ja not_active Expired - Fee Related
-
2013
- 2013-07-10 JP JP2014535412A patent/JPWO2014041885A1/ja active Pending
- 2013-07-10 WO PCT/JP2013/068827 patent/WO2014041885A1/ja active Application Filing
- 2013-07-10 CN CN201380047772.4A patent/CN104661659B/zh not_active Expired - Fee Related
- 2013-07-10 IN IN461DEN2015 patent/IN2015DN00461A/en unknown
-
2015
- 2015-02-25 US US14/630,911 patent/US20150164823A1/en not_active Abandoned
- 2015-12-30 US US14/984,752 patent/US9554990B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
Kim et al. Journal Of Medicinal Food, 2011, 14(6), 573-583 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3486353A4 (en) * | 2016-06-28 | 2020-03-04 | Kuraray Co., Ltd. | COMPOSITION FOR REMOVAL OF IRON SULFIDE |
Also Published As
Publication number | Publication date |
---|---|
IN2015DN00461A (enrdf_load_stackoverflow) | 2015-06-26 |
US20160106668A1 (en) | 2016-04-21 |
JPWO2014041885A1 (ja) | 2016-08-18 |
WO2014041885A1 (ja) | 2014-03-20 |
CN104661659A (zh) | 2015-05-27 |
US9554990B2 (en) | 2017-01-31 |
JP5951426B2 (ja) | 2016-07-13 |
JP2015178459A (ja) | 2015-10-08 |
CN104661659B (zh) | 2017-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5876205B2 (ja) | D−ソルボースからなる甘味料におけるd−ソルボースの甘味の不足や、甘味の持続を改良する方法 | |
JPWO2007000985A1 (ja) | ヘモグロビン尿症またはミオグロビン尿症の予防または治療用組成物 | |
KR101413207B1 (ko) | 염증성 질환의 예방 또는 치료용 약학 조성물 및 건강기능식품 | |
JP7503179B2 (ja) | インスリン抵抗性改善用組成物 | |
TW200406159A (en) | Calcium absorption enhancer | |
EP1254658A1 (en) | Remedies | |
US9554990B2 (en) | Cholecystokinin secretion-promoting composition | |
JP6469394B2 (ja) | アポトーシス抑制剤 | |
JPWO2009142320A1 (ja) | アトピー性皮膚炎予防剤及び/または治療剤 | |
JP6265335B2 (ja) | 骨密度増加剤、破骨細胞活性抑制剤及び骨リモデリング改善剤 | |
JP6077331B2 (ja) | Trpa1活性化組成物 | |
JP7265591B2 (ja) | 脳機能改善用組成物 | |
KR102571732B1 (ko) | 페디오코쿠스 펜토사세우스 kid7 균주를 포함하는 알코올성 간질환의 예방, 개선, 또는 치료용 조성물 | |
WO2015140124A1 (en) | Composition comprising cinnamaldehyde and zinc to improve swallowing | |
JP2007238581A (ja) | 関節炎改善用組成物 | |
JP2009046420A (ja) | 免疫賦活剤及びそれを含有する飲食品 | |
KR20220118504A (ko) | 비만 억제용 조성물 | |
JP7659690B1 (ja) | 老化細胞除去剤 | |
JP5943516B2 (ja) | D−ソルボースを有効成分とする生体機能改善用甘味料 | |
KR102759442B1 (ko) | 복분자 추출물을 포함하는 항바이러스용 조성물 | |
JP7660846B2 (ja) | 毛細血管障害抑制剤、毛細血管障害改善剤、及び毛細血管新生促進剤 | |
WO2025142973A1 (ja) | 老化細胞除去剤及び運動機能低下抑制剤 | |
KR20190134958A (ko) | 올레아놀릭산을 유효성분으로 포함하는 톡소플라즈마증의 치료 또는 예방용 조성물 | |
KR20190125133A (ko) | 우르솔릭산을 유효성분으로 포함하는 톡소포자충증의 치료 또는 예방용 항톡소포자충증 조성물 | |
KR20200128478A (ko) | 우르솔릭산을 유효성분으로 포함하는 톡소포자충증의 면역증강용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: J-OIL MILLS, INC., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HARA, HIROSHI;HIRA, TOHRU;NISHIYAMA, CHIGUSA;AND OTHERS;SIGNING DATES FROM 20150126 TO 20150212;REEL/FRAME:035026/0357 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |